Study Indicates Broncho-Vaxom® Lowers Respiratory Infection Rates

A large multi-country study, REACH, presented preliminary findings suggesting that Broncho-Vaxom® (OM-85) significantly reduced respiratory tract infection rates. The research observed a 28-41% reduction over 12 to 24 months in over 15,000 patients. These real-world results offer insights into the treatment's effectiveness.